All News

21 October 2011

STELARA (ustekinumab)is Effective, Well-Tolerated and Improves Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis Inadequately Responsive to Methotrexate[1,2]Antibodies

20 October 2011

ImmunoGen, Inc. Earns Milestone With Start of SAR3419 Phase II TestingAntibodies

20 October 2011

Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two YearsAntibodies

20 October 2011

Biogen Idec and Elan Receive Notification of PDUFA Date ExtensionAntibodies

20 October 2011

Evotec and APEIRON Biologics Start Next Project on the Cbl-b TargetAntibodies

19 October 2011

Arsanis Receives Grant from the Austrian Research Promotion Agency for Pre-Clinical and Clinical Development of Monoclonal Antibodies Against Severe Nosocomial InfectionsAntibodies

18 October 2011

Halozyme Announces Positive Results from Roche’s Subcutaneous Herceptin Phase 3 TrialAntibodies

17 October 2011

Update on Large Scale Manufacturing Outcomes for PAT-SM6Antibodies

17 October 2011

Lpath Initiates Dosing of iSONEP in Second of Two Proof-of-Concept TrialsAntibodies

13 October 2011

Micromet Obtains FDA Feedback on Registration Strategy for Blinatumomab in Relapsed/Refractory ALLAntibodies

13 October 2011

Emisphere Technologies, Inc. Reports Notification of First Interpretable Results on 2nd Phase III Study of Oral Calcitonin in Osteoarthritis PatientsAntibodies

11 October 2011

Study Shows That Roche’s Investigational Drug for Alzheimer’s Disease Removes Amyloid Plaques From the BrainAntibodies

11 October 2011

Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer PatientsAntibodies

10 October 2011

Daval International Announces Positive Phase II Results for AIMSPRO as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)Antibodies

6 October 2011

Peregrine Completes Patient Enrollment in Second-Line Non-Small Cell Lung Cancer Trial; Data to Be Unblinded in First Half 2012Antibodies

5 October 2011

iBio Announces Production of Biosimilar Rituximab with its iBioLaunch TechnologyAntibodies

4 October 2011

X-BODY Biosciences Enters Into R&D Partnership With Tanabe Research Laboratories U.S.A., Inc. to Generate Antibody Therapeutics for Autoimmune DisordersAntibodies

3 October 2011

MedImmune In-Licenses Cancer Immunotherapy Tremelimumab from PfizerAntibodies

30 September 2011

Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid TumorsAntibodies

29 September 2011

Lpath Initiates Dosing of iSONEP in First of Two Proof-of-Concept TrialsAntibodies

29 September 2011

Children’s Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301)Antibodies

27 September 2011

Novartis receives approval in Japan for two innovative therapies, Gilenya in MS and Ilaris in CAPSAntibodies

26 September 2011

Roche’s investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancerAntibodies

26 September 2011

Abbott Japan and Eisai Submit Application in Japan for Additional Indication of Humira (adalimumab), a Fully Human Anti-TNF-± Monoclonal Antibody, for Inhibition of Structural Damage of Joints in Rheumatoid ArthritisAntibodies

26 September 2011

Peregrine Completes Patient Enrollment in Randomized Phase II HCV Trial for BavituximabAntibodies

26 September 2011

REMICADE Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative ColitisAntibodies

26 September 2011

Impact of CATT Study Findings Evident in Significant Reported Changes in Prescribing of Genentech’s Avastin and Lucentis for the Treatment of Wet AMD According to a BioTrends ReportAntibodies

23 September 2011

Alexion Receives CHMP Positive Opinion for Soliris (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the European UnionAntibodies

23 September 2011

Immunomedics Announces Partial Clinical Hold on Clivatuzumab Tetraxetan Clinical TrialAntibodies

23 September 2011

ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin’s LymphomaAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

DLL3-Targeted Immunotherapy Candidates Pipeline Review

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review

CD73 Inhibitor Pipeline Review

Report Package: “Drug the Undruggable” Technologies

5T4-Targeted Immunotherapy Candidates Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Aflibercept (Eylea) Biosimilars Pipeline Review